Zusammenfassung
Ergänzend kann man festhalten, daß Dopaminrezeptoragonisten eine direkte Stimulation von Dopaminrezeptorsubtypen ermÖglichen. Damit reduzieren sie die Freisetzung von Dopamin aus präsynaptischen Nervenenden und verringern dadurch mÖglichen oxidativen Streß (Davis et al. 1997, Melamed 1995); zum Beispiel gelingt experimentell die UnterdrÜckung der Impulsrate von dopaminergen Neuronen der Substantia nigra pars compacta durch Pramipexol (Piercey et al. 1996).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Bernocchi G, Gerzeli G, Scherini E, Vignola C (1993) Neuroprotective effects of α-dihydro-ergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4phenyl-1,2,3,6-tetrahydropy ridine. Acta Neuropathol 85: 404–413
Canonico PL, Sortino MA, Favit A et al. (1993) Dihydroergocryptine protects from acute experimental allergic encephalomyelitis in the rat. Funct Neurol 8: 183–188
Carvey PM, Pieri S, Ling ZD (1997) Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 104: 209–228
Cassels BK, Asencio M, Conget P, Speisky H, Videla LA, Lissi EA (1995) Structure-antioxidative activity relationships in benzylisoquinoline alkaloids. Pharmacol Res 31: 103–107
Coppi G (1995) Neuroprotective activity of alpha-dihydroergocryptine in animal models. J Neural Transm [Suppl] 45: 307–317
Davis MD, Heffner TG, Cooke LW (1997) Dopamine agonist-induced inhibition of neurotransmitter release from the awake squirrel monkey putamen as measured by microdialysis. J Neurochem 68: 659–666
Delbarre B, Delbarre G, Rochat C, Calinon F (1995) Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, amino acids, and free radicals in gerbil brain after cerebral ischemia. Mol Chem Neuropathol 26: 43–52
Felten DL, Felten SY, Fuller RW, Romano TD, Smalstig EB, Wong DT, Clemens JA (1992) Chronic dietary pergolide preserves nigrostriatal integrity in aged-Fischer-334 rats. Neurobiol Aging 13: 339–351
Gassen M, Glinka Y, Pinchasi B, Youdim MB (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219–225
Hall E D, Andrus P K, Oostveen J A, Althaus J S, Von Voigtlander PF (1996) Neuroprotective effects of the dopamine D-2/D-3 agonist pramipexole against postischemic or meth-amphetamine-induced degeneration of nigro-striatal neurons. Brain Res 742: 80–88
Kitamura Y, Kohno Y, Nakazawa M, Nomura Y (1997) Inhibitory effets of talipexole and pramipexole on MPTP-Induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol 74: 51–57
Melamed E (1995) Does treatment with dopamine agonists affect utilization of exogenous levo-dopa in the parkinsonian striatum? J Neural Transm [Suppl] 45: 57–60
Nishibayashi S, Asanuma M, Kohno R, Gomez-Vargas M, Ogawa N (1996) Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 67: 2208–2211
Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxy-dopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657: 207–213
Opacka-Juffry J, Wilson AW, Blunt SB (1998) Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res 810: 27–33
Piercey MF, Hoffmann WE, Smith MW, Hyslop DK (1996) Inhibition of dopamine neuron firing by pramipexole, a D3-prefering dopamine agonist: comparison to other dopamine agonists. Eur J Pharmacol 312: 35–44
Renodon A, Boncher JL, Sari M A, Delaforge M, Ouazzani J, Mansury D (1997) Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects. FEBS Lett 406: 33–36
Sam EE, Verbeke N (1995) Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism. J Neural Transm [PD-Sect] 10: 115–127
Tanaka M, Sotomatsu A, Yoshida T, Hirai S (1995) Inhibitory effects of bromocriptine on phospholipid peroxidation induced by dopa and iron. Neurosci Lett 183: 116–119
Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62: 1034–1038
Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W (1999) Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity. Life Sci 64: 1275–1285
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Wien
About this chapter
Cite this chapter
Riederer, P. (1999). Dopaminrezeptoragonisten: Der neuroprotektive Ansatz. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_28
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6400-6_28
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7315-2
Online ISBN: 978-3-7091-6400-6
eBook Packages: Springer Book Archive